JP2022520817A - Ｆｃｍｒ結合分子およびそれらの使用 - Google Patents

Ｆｃｍｒ結合分子およびそれらの使用 Download PDF

Info

Publication number
JP2022520817A
JP2022520817A JP2021547401A JP2021547401A JP2022520817A JP 2022520817 A JP2022520817 A JP 2022520817A JP 2021547401 A JP2021547401 A JP 2021547401A JP 2021547401 A JP2021547401 A JP 2021547401A JP 2022520817 A JP2022520817 A JP 2022520817A
Authority
JP
Japan
Prior art keywords
seq
antibody
fcmr
amino acid
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520817A5 (https=
Inventor
ブロックス，リチャード
エム． メイソン，ジャクリーン
アール． ブレイ，マーク
Original Assignee
ユニバーシティ ヘルス ネットワーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ ヘルス ネットワーク filed Critical ユニバーシティ ヘルス ネットワーク
Publication of JP2022520817A publication Critical patent/JP2022520817A/ja
Publication of JP2022520817A5 publication Critical patent/JP2022520817A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021547401A 2019-02-15 2020-02-14 Ｆｃｍｒ結合分子およびそれらの使用 Pending JP2022520817A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806237P 2019-02-15 2019-02-15
US62/806,237 2019-02-15
PCT/CA2020/050195 WO2020163962A1 (en) 2019-02-15 2020-02-14 Fcmr-binding molecules and uses thereof

Publications (2)

Publication Number Publication Date
JP2022520817A true JP2022520817A (ja) 2022-04-01
JP2022520817A5 JP2022520817A5 (https=) 2023-02-21

Family

ID=72043773

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547401A Pending JP2022520817A (ja) 2019-02-15 2020-02-14 Ｆｃｍｒ結合分子およびそれらの使用

Country Status (14)

Country Link
US (1) US12286476B2 (https=)
EP (1) EP3924388A4 (https=)
JP (1) JP2022520817A (https=)
KR (1) KR20210139273A (https=)
CN (1) CN113993895A (https=)
AU (1) AU2020222408A1 (https=)
BR (1) BR112021016102A2 (https=)
CA (1) CA3130225A1 (https=)
EA (1) EA202192254A1 (https=)
IL (1) IL285585A (https=)
MX (1) MX2021009767A (https=)
SG (1) SG11202108837WA (https=)
TW (1) TWI857009B (https=)
WO (1) WO2020163962A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021009767A (es) 2019-02-15 2021-11-17 Univ Health Network Moleculas de union de fmcr y usos de las mismas.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523264A (ja) * 2013-07-03 2016-08-08 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏに対する抗体
US20160347854A1 (en) * 2015-05-28 2016-12-01 Universitaet Zu Koeln Anti-TOSO chimeric antigen receptor and its use
JP2017508744A (ja) * 2014-03-07 2017-03-30 ユニバーシティ ヘルス ネットワーク 免疫応答を調節するための方法及び組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
CA2867444C (en) * 2012-03-16 2021-04-13 University Health Network Compositions containing soluble toso protein and uses thereof
EP2970451A1 (en) * 2013-03-14 2016-01-20 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
US20180201676A1 (en) 2015-02-11 2018-07-19 University Health Network Methods and compositions for modulating lilr proteins
WO2018119425A2 (en) 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
MX2021009767A (es) 2019-02-15 2021-11-17 Univ Health Network Moleculas de union de fmcr y usos de las mismas.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523264A (ja) * 2013-07-03 2016-08-08 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏに対する抗体
JP2017508744A (ja) * 2014-03-07 2017-03-30 ユニバーシティ ヘルス ネットワーク 免疫応答を調節するための方法及び組成物
US20160347854A1 (en) * 2015-05-28 2016-12-01 Universitaet Zu Koeln Anti-TOSO chimeric antigen receptor and its use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KUBAGAWA, Y ET AL.: "Monoclonal Antibodies Specific for Human IgM Fc Receptor Inhibit Ligand-binding Activity", MONOCLONAL ANTIBODIES IN IMMUNODIAGNOSIS AND IMMUNOTHERAPY, vol. 33, no. 6, JPN6024004960, 2014, pages 393 - 400, ISSN: 0005750876 *
NGUYEN, XUAN-HUNG ET AL.: "Toso regulates the balance between apoptotic and nonapoptotic death receptor signaling by facilitati", BLOOD, vol. 118, no. 3, JPN6024004961, 2011, pages 598 - 608, ISSN: 0005750877 *
YI, T ET AL.: "Anti-TOSO antibody treatment promotes T cell activation-induced cell death (AICD) in vitro and in vi", CHINESE SCIENCE BULLETIN, vol. 59, JPN6024004958, 2014, pages 1374 - 1385, ISSN: 0005750875 *

Also Published As

Publication number Publication date
EP3924388A1 (en) 2021-12-22
BR112021016102A2 (pt) 2021-11-09
SG11202108837WA (en) 2021-09-29
US12286476B2 (en) 2025-04-29
EP3924388A4 (en) 2023-02-15
EA202192254A1 (ru) 2021-11-29
CA3130225A1 (en) 2020-08-20
TWI857009B (zh) 2024-10-01
AU2020222408A1 (en) 2021-09-09
MX2021009767A (es) 2021-11-17
US20220089725A1 (en) 2022-03-24
KR20210139273A (ko) 2021-11-22
TW202035461A (zh) 2020-10-01
WO2020163962A1 (en) 2020-08-20
IL285585A (en) 2021-09-30
CN113993895A (zh) 2022-01-28

Similar Documents

Publication Publication Date Title
JP6956083B2 (ja) Ｃｄ３とｃｄ３８とを結合するヘテロ二量体抗体
TWI838621B (zh) 具有經修飾重鏈恆定區之多特異性重鏈抗體
JP2023106405A (ja) ＩＬ－１５／ＩＬ－１５ＲアルファＦｃ融合タンパク質およびＰＤ－１抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
JP6205363B2 (ja) ハイブリッド定常領域
CN111971090B (zh) 双特异性egfr/cd16抗原结合蛋白
JP2022512865A (ja) 相同二量体型二重特異性抗体およびその調製方法と使用
JP7596298B2 (ja) 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体
WO2018205985A1 (zh) 含有TGF-β受体的融合蛋白及其医药用途
CN115894703A (zh) 具有经修饰重链恒定区的多特异性重链抗体
TW202235431A (zh) 腫瘤特異性可裂解連接子
WO2023051727A1 (zh) 结合cd3的抗体及其用途
CN111133007A (zh) 与胞外酶结合的重链抗体
JP2025537484A (ja) Ｉｌ－１８受容体に対するヘテロマーアゴニスト抗体
JP2022522815A (ja) Ｔｓｇ－６抗体およびその用途
JP2022517809A (ja) Ｌｉｌｒｂ３結合分子とその使用
JP2024512422A (ja) Ｌｉｌｒｂ１及びｌｉｌｒｂ２に結合する分子、ならびにその使用
JP2022520817A (ja) Ｆｃｍｒ結合分子およびそれらの使用
WO2022037582A1 (zh) 抗cd3和抗cldn-18.2双特异性抗体及其用途
HK40088767A (zh) 一种双特异性多肽复合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260224